Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK’d, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are said to looking to buy the startup.
Continue reading Inside Wall Street: This New Antidepressant Maker Has Lots of Folks Excited
Inside Wall Street: This New Antidepressant Maker Has Lots of Folks Excited originally appeared on DailyFinance on Mon, 25 Oct 2010 07:30:00.
Filed Under: Company News, Columns, Investing, Health Care, Pfizer, Stock Picks, Merck, GlaxoSmithKline, Eli Lilly